Drug Versus Radioactive Treatment of Graves' Disease - Metabolic Outcomes

Program: Abstracts - Orals, Poster Previews, and Posters
Session: SAT 238-269-HPT Axis Biology, Health Disparities, Non-Neoplastic Thyroid Disorders, and Thyroid Immunology (posters)
Bench to Bedside
Saturday, April 2, 2016: 1:15 PM-3:15 PM
Exhibit/Poster Hall (BCEC)

Poster Board SAT 240
Elena Izkhakov*, Mariana Yaron, Karen Michele Tordjman, Yona Greenman and Naftali Stern
Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Background: Weight gain is a common complaint in patients treated for Graves' disease.We compared rates of weight gain, hypertension, glucose intolerance, and disturbance in lipid profile, following radioactive iodine (RAI) and antithyroid drug treatment in Graves’ patients.

Methods: This is a cross-sectional study of patients with Graves' disease treated at one institute between the years 2003-2010.Patients underwent physical examinations, which included height, weight and blood pressure (BMI calculated); 24 hour ambulatory blood pressure monitoring and blood measurements of fasting glucose, thyroid function and lipid profile. Additionally, we compared current to self reported past data regarding weight and BMI.

Results: Of 113 patients, 68 (53 women) received RAI therapy and 45 (36 women) were treated with thioamides. Mean ages were 53 (95% CI: 50-56) and 48 (95% CI: 44-52) years, respectively, and median duration of disease: 5 (IQR: 4-6) and 6 (IQR: 3-8) years. After adjustment for sex, age and disease duration, body weight increased by a mean of 9.9% for RAI treated patients and 4.6% for medically treated subjects (P<0.025). Newly diagnosed dyslipidemia (detected after the diagnosis/treatment of Graves' disease) was more common in RAI-treated than in medically treated patients (37.7% vs 17.1%;  P<0.028).  Further, RAI treated patients had a higher number of components of the metabolic syndrome compared to the drug treated patients (2.0 vs 1.4; p<0.018)

Conclusions: The results of this study are consistent with some previously reported data concerning the outcome of the main two modalities of the treatment of hyperthyroidism. The key findings in our study are that compared to medically treated patients with Graves' disease, RAI-treated subjects with the same disease  experienced a significantly larger increase of the body weight and had a higher rate of new-onset dyslipidemia  with significantly higher number of components of the metabolic syndrome.

Further information will be obtained by continued monitoring of our study population in order to collect information that will allow longitudinal comparison of each patient's condition at least in two separate time points.

Nothing to Disclose: EI, MY, KMT, YG, NS

*Please take note of The Endocrine Society's News Embargo Policy at https://www.endocrine.org/news-room/endo-annual-meeting/pr-resources-for-endo